AMGN logo

Amgen Inc.

AMGN
Healthcare|Drug Manufacturers - General|US
$460.42
+0.14 (+0.03%)
DCF Value
$902.10
Graham Number
$101.79
Cash / Share
$24.38

About

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

Stock Price

+45.9%(1Y)
1M
+13.0%
3M
+12.0%
6M
+38.8%
YTD
+40.7%
1Y
+42.3%
3Y
+68.5%
5Y
+117.8%

Pipeline Summary

542 total trials
140
Phase 1
195
Phase 2
112
Phase 3
38
Phase 4
Completed: 377Terminated: 57Not Yet Recruiting: 6Recruiting: 36Active: 27Unknown: 20Withdrawn: 16By Invitation: 1No Longer Available: 1Suspended: 1

Active Trials (63)

TIDHI Mental Health in IBD Patients Study
NCT07013578Crohn Disease (CD)
N/ARecruiting
Enrollment: 100 participants
CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
NCT04151342Cancer
Recruiting
Enrollment: 5,500 participants
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
NCT03289299Smoldering Multiple Myeloma
Phase 2Active
Enrollment: 87 participants
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810Non Small Cell Lung Cancer
Phase 1Phase 2Active
Enrollment: 153 participants
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
NCT05848687Lymphoblastic Leukemia
Phase 1Phase 2Recruiting
Enrollment: 90 participants

BioScore

6.8/10
Buy

Key Facts

Market Cap$248.92B
Employees31,500 (+13% YoY)
CEORobert A. Bradway
IPO DateJun 17, 1983
Beta0.42
52-Week Range$312.39 – $483.99
Avg Volume2,728,622
ExchangeNASDAQ
Websiteamgen.com

Ownership

Float99.8%
Shares Outstanding540.6M

Recent Insider Trades

Gibbs David WOTHER
Oct 26, 20260 shares
Dittrich Thomas J.W.OTHER
Sep 1, 20260 shares
Dittrich Thomas J.W.OTHER
Aug 7, 202717,201 shares @ $410.95
Khosla RachnaOPTION EX.
Aug 13, 20261,252 shares @ $162.60
Khosla RachnaSELL
Aug 11, 20262,000 shares @ $412.57

Peers

ABBVAbbVie Inc.
$514.78B
AZNAstraZeneca PLC
$289.14B
BMYBristol-Myers Squibb Company
$127.02B
GSKGSK plc
$102.02B
JNJJohnson & Johnson
$664.95B
LLYEli Lilly and Company
$1273.77B
MRKMerck & Co., Inc.
$361.96B
NVSNovartis AG
$307.00B
Data last updated: Nov 9, 2026, 03:54 AM